Organigram Global Inc. · TSX:OGI
Organigram Global — Q4 2019 Earnings Presentation
13 slides from Organigram Global's earnings presentation, Nov 25, 2019
Slide 1: Q4 and Fiscal 2019 Results
Q4 and Fiscal 2019 Results November 25, 2019 NASDAQ (OGI) TSX (OGI)
Slide 2: Cautionary Statement
Cautionary Statement This document is current as of November 24, 2019, except where otherwise stated. The information contained in this presentation is provided by Organigram ("OGI" or the “Company’) for informational purposes only and does not constitute an offer to issue or arrange to issue, or th
Slide 3: Fiscal 2019 Financial Results
Fiscal 2019 Financial Results NET REVENUE * 2019 net revenue grew 547% from 2018 » YTD - estimated national market share of ~10% in GROSS MARGIN before FV CHANGES to BIO ASSETS & INVENTORIES * Gross margin before fair value changes to bio assets and inventory sold increased 575% from 2018 ADJUSTED E
Slide 4: Target Production Capacity
TARGET PRODUCTION CAPACITY" Phase 4 Expansion of Moncton Campus 113,000 kg/yr 24,000 kg/yr 70% . . oe CONSTRUCTION * Current licensed production capacity is 76,000kg/yr": 89,000 kg/yr COMPLETED with all Phase 4A and ~50% of Phase 4B rooms 13,000 KG/YR . APPLIED FOR licensed LICENSING * Awaiting lice
Slide 5: Cowen's THC Tracker: U.S. Brands
5 1 QUICK TAKE - Cannabis - Cowen's THC Tracker: U.S. Brands - Cowen and Company, March 29, 2019
Slide 6: Innovative Vaporizer Experiences
Innovative Vaporizer Experiences * Selected as one of the Canadian partners for PAX Era, the premium closed loop vaporizer system created by PAX Labs, Inc. » PAX Labs, Inc. - a leader in the design and development of premium app-controlled vape technologies for cannabis * Selected as exclusive Canad
Slide 7: Premium Cannabis-infused Chocolates
Premium Cannabis-infused Chocolates * $15 million investment in high-speed, high-capacity, fully- automated production line that includes advanced engineering, robotics, high-speed labeling automated carton packing * Installation of the production line has been completed and expect the licensing and
Slide 8: Proprietary Nano-Emulsification Technology
Proprietary Nano-Emulsification Technology Powdered Beverage Products * Expect to launch dried powder formulation beverage products in Q2 calendar 2020 based on expected licensing for the production area and equipment delivery and commissioning schedules * Proprietary nano-emulsion technology, devel
Slide 9: Award-winning Products and Brands
Award-winning Products and Brands Won Top Product Award in the High THC Bottled Oil Top High THC Category for our medical bp product, Rossignol WINNER 2019 ORGANIGRAM Runner-up for medical ROSSIGNOL High THC Bottled Oil Banook and recognized in 7 other categories Top High THC First runner up: ORGANI
Slide 10: Phase Refurbishment for Edibles and Derivative Products
Phase 5 - Refurbishment for Edibles and Derivative Products 56,000 square feet within existing Moncton Campus facility being refurbished and designed under EU GMP standards for: * An edibles and derivative production facility; and * Additional extraction capacity Primary construction largely complet
Slide 11: Liquidity and Capital
Liquidity and Capital * Cash and short-term investments of $47.9M as at fiscal 2019 year end * Generated positive adjusted EBITDA of $19.9M1’ in 2019 ° $50M in undrawn capacity on total term loan of $115M * Arevolver available of up to $25M to be drawn against specified receivables * Credit facility
Slide 12: Q4 and Fiscal 2019 results table
(in 000s) Q4-19 Q4-18 % CHANGE FISCAL 2019 FISCAL 2018 % CHANGE 12
Slide 13: Adjusted EBITDA reconciliation
(in 000s) Q4-2019 Q4-2018 Fiscal 2019 Fiscal 2018 This is a non-IFRS measure and the Company calculates Adjusted EBITDA adjusted EBITDA from continuing operations as net income Net income (loss) from continuing $ (22,456) $ 18,091 $ (9,505) $ 22,123 operations (earnings) before: interest expense, ne